Once Weekly Efsitora Shows Non-Inferiority in A1c Reductions Compared With Daily Basal Insulin
Once weekly insulin efsitora alfa (efsitora; Eli Lilly and Company) demonstrated non-inferiority in A1c reduction when compared to commonly used daily basal insulins, according to results from the QWINT-2 (NCT05362058) and QWINT-4 (NCT05462756) phase 3 …